In this episode, faculty discuss the importance of early intervention when treating glaucoma patients. Faculty review the main MIGS patient types: pseudophakic patients, in combination with cataract surgery, and in pre-cataract patients.
Supported by an unrestricted educational grant from Sight Sciences.
Compare and contrast standalone and cataract MIGS (minimally invasive glaucoma surgery) patients: Patient demographics, surgical procedure, and patient follow-up parameters
Kristopher May, OD
Coldwater Vision Center
Coldwater, MS
Deborah Ristvedt, DO
Ophthalmologist Surgeon
Vance Thompson Vision
Bozeman, MT
Leslie O’Dell, OD, FAAO
Clinical Director
Medical Optometry America
York, PA
Justin Schweitzer, OD, FAAO
Vance Thompson Vision
Sioux Falls, SD
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:
Kristopher May, OD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon, and Sight Sciences. Speaker’s Bureau: Alcon, Bausch + Lomb, and Sight Sciences.
Deborah Ristvedt, DO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Glaukos, and Sight Sciences. Grant/Research Support: Allergan. Speaker’s Bureau: Alcon, and Glaukos.
Leslie O’Dell, OD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie, Allergan, Bausch + Lomb, Dompe, Eyevance, Johnson & Johnson Vision, Kala Pharmaceuticals, Novartis, Oyster Point, Pharma, Sun Pharmaceutical Industries, Sight Sciences, and Tarsus. Speaker's Bureau: Allergan, Johnson & Johnson Vision, and Sight Sciences.
Justin Schweitzer, OD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon, Allergan, Bausch + Lomb, Dompé, EyePoint, Horizon, Ocular Therapeutix, and Reichert. Grant/Research Support: Glaukos. Speaker’s Bureau: Aerie, Alcon, Allergan, Bausch + Lomb, Glaukos, Quidel, Sight Sciences, and Sun Pharmaceutical Industries. Share/Stockholder: Equinox.
The Evolve Medical Education or The Fundingsland Group staff and planners have no financial relationships with commercial interests.
OFF-LABEL STATEMENT This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. DISCLAIMER The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, The Fundingsland Group or Sight Sciences.
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Christina Y. Weng, MD, MBA, FASRS
Mark T. Dunbar, OD, FAAO
David A. Eichenbaum, MD, FAAO
Jaclyn Garlich, OD, FAAO
Mohammad R. Rafieetary, OD, FAAO, FORS, ABO
John Kitchens, MD
Sara LeMay, OD
Sunir J. Garg, MD, FACS, FASRS
Charles C. Wykoff, MD, PhD, FACS
Mark T. Dunbar, OD, FAAO
David Eichenbaum, MD
